Intraocular inflammation following intravitreal injection of bevacizumab

  • Sophie J. Bakri
  • Theresa A. Larson
  • Albert O. Edwards
Case Report



Injection of drugs into the vitreous can lead to intraocular inflammation through infectious and non-infectious processes. Failure to recognize an eye with anterior chamber and vitreous cell as sterile inflammation can lead to unnecessary treatment for endophthalmitis.


Four cases of uveitis following intravitreal bevacizumab (Avastin) for exudative age-related macular degeneration are described followed by review of the literature.


Four patients presented with uveitis. Two patients presented with pain and red eye associated with iritis and two patients with vitritis, several days following intravitreal injection of bevacizumab. No paracentesis was performed and no corneal epithelial defect was created. Both patients with iritis were presumed to have sterile intraocular inflammation since the anterior chamber cell was much greater than the vitreous cell and resolved with cycloplegic and topical corticosteroid therapy. The third patient presented only with vitreous cell which resolved without therapy. The fourth patient had anterior chamber cell and vitreous cell with clumps, which resolved with topical prednisolone acetate. The inflammation resolved in all cases within 1 to 2 weeks.


There are few published cases of uveitis following bevacizumab. With its rising use, it is important to be aware of its potential to be associated with intraocular inflammation.


Avastin Bevacizumab VEGF Macular degeneration Uveitis Vitritis Inflammation 


  1. 1.
    Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390PubMedCrossRefGoogle Scholar
  2. 2.
    Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F (2007) Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocular Pharmacol Ther 23:240–242CrossRefGoogle Scholar
  3. 3.
    Ho J, Loewenstein JI (2007) Endophthalmitis associated with intravitreal injections. Int Ophthalmol Clin 47:199–208PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRefGoogle Scholar
  5. 5.
    Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF (2003) Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 136:791–796PubMedCrossRefGoogle Scholar
  6. 6.
    Taban M, Singh RP, Chung JY, Lowder CY, Perez VL, Kaiser PK (2007) Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophth 144:50–54PubMedCrossRefGoogle Scholar
  7. 7.
    Pieramici DJ, Avery RL, Castellarin AA, Rabena M (2006) Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 26:841–842PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048–1053PubMedCrossRefGoogle Scholar
  9. 9.
    Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA (2003) Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 121:1279–1282PubMedCrossRefGoogle Scholar
  10. 10.
    Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth S (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26:877–881PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sophie J. Bakri
    • 1
  • Theresa A. Larson
    • 1
  • Albert O. Edwards
    • 1
  1. 1.Department of OphthalmologyMayo ClinicRochesterUSA

Personalised recommendations